Abivax pares gain after denying AstraZeneca speculation
2026-03-12 10:41:35 ET
More on Abivax
- Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
- Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
- Abivax CEO responds to Lilly acquisition rumors
- Key deals this week: Micron Technology, Worthington Steel, Boston Scientific, CrowdStrike and more
- Seeking Alpha’s Quant Rating on Abivax
Read the full article on Seeking Alpha
For further details see:
Abivax pares gain after denying AstraZeneca speculationNASDAQ: ABVX
ABVX Trading
-1.64% G/L:
$116.16 Last:
303,110 Volume:
$117.38 Open:



